TGR-1202

Phase 2Small molecule

TTG Therapeutics, Inc.

TGR-1202 is one of 146 small molecule programs targeting Polycythemia Vera. It is currently in Phase 2.

Indications

Total Trials

Active Trials

145

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

LymphomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Follicular LymphomaActive, not recruiting

Polycythemia VeraPhase 1

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

Follicular LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

TGR-1202

TTG Therapeutics, Inc.

Phase 2

2 3

Oncaspar

SServier

Preclinical

15 4

Velban

EEastern Cooperative Oncology Group

Preclinical

15 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Relapsed/refractory

NCT03283137

Clinical

Trials by Indication[1]

Lymphoma2 trials

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Terminated·—·Phase 1/2·NCT02867618·14 enrolled

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Completed·TTG Therapeutics, Inc.·Phase 1·NCT02164006·16 enrolled

Chronic Lymphocytic Leukemia2 trials

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Terminated·TTG Therapeutics, Inc.·Phase 3·NCT02612311·603 enrolled

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Completed·TTG Therapeutics, Inc.·Phase 1·NCT02100852·19 enrolled

Treatment1 trial

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Terminated·TTG Therapeutics, Inc.·Phase 2·NCT03207256·51 enrolled

Safety and Efficacy1 trial

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Completed·—·Phase 1·NCT02268851·45 enrolled

Relapsed/Refractory1 trial

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

Active, not recruiting·UUniversity of Chicago·Phase 1·NCT03283137·20 enrolled

4 more indications

Refractory Solid Tumors1 trial

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Completed·TTG Therapeutics, Inc.·Phase 1·NCT02574663·66 enrolled

Follicular Lymphoma1 trial

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Terminated·—·Phase 2·NCT03178201·5 enrolled

Polycythemia Vera1 trial

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02493530·60 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Completed·TTG Therapeutics, Inc.·Phase 1·NCT01767766·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for TGR-1202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TGR-1202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TGR-1202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TG Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTG Therapeutics, Inc.

TGR-1202

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lymphoma2 trials

Chronic Lymphocytic Leukemia2 trials

Treatment1 trial

Safety and Efficacy1 trial

Relapsed/Refractory1 trial

Refractory Solid Tumors1 trial

Follicular Lymphoma1 trial

Polycythemia Vera1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

References

Drug Info

Quick Facts

Related News